All Eyes on Allergan: Drug Company’s Unprecedented Move Raises Questions for Patent and Drug Law (Part II) · Electoral Command Center

As discussed in Part I of this two-part Sidebar, on September 8, 2017, Allergan, Inc. announced that it assigned its rights to six patents covering its dry-eye drug Restasis (Rest…